ClinicalTrials.gg
Active, not recruitingNCT06141486FREVIVAUpdated Nov 9, 2026

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

A Phase 3 interventional study of Frexalimab and Placebo in Multiple Sclerosis, sponsored by Sanofi. Active, not recruiting at 311 sites in 27 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
943
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies in Multiple Sclerosis by Sanofi — 3 open to participants now, 6 under way, 4 of them phase 3. Multiple Sclerosis · Sanofi.

Enrollment
8th of 41
943 · median 166
Started
2023
with 1 other
Phase 3
18 of 44
2 open now
Registered
40th of 44
by date

Among the 44 studies in Multiple Sclerosis by Sanofi, this one is the 8th largest by enrollment of the 41 interventional ones that give a count, is one of 2 that started in 2023, is one of 18 in phase 3, and was the 40th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

3 of the 44 studies in Multiple Sclerosis by Sanofi are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Multiple Sclerosis by Sanofi, or all of them as a file.
02

Study summary

The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to 36 months double-blind administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with nrSPMS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include:

  • This event-driven study will end when the target number of 6-month cCDP events is achieved, and the study is expected to last 43 months from randomization of the first participant to the common study end.
  • The number of scheduled visits will be up to 25 (including 3 follow-up visits) with a visit frequency of every month for the first 6 months and then every 3 months.
  • If the prespecified number of events for 6-month cCDP is not reached by V21/W180, scheduled visits will continue every 3 months.
03

Conditions studied

  • Multiple Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must have a previous diagnosis of RRMS in accordance with the 2017 revised McDonald criteria.
  • Participant must have a current diagnosis of SPMS in accordance with the clinical course criteria revised in 2013 endorsed by an Adjudication Committee.
  • Participant must have documented evidence of disability progression observed during the 12 months before screening. Eligibility will be analyzed by an Adjudication Committee.
  • Absence of clinical relapses for at least 24 months.
  • The participant must have an EDSS score at screening from 3.0 to 6.5 points, inclusive.
  • use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • For patients eligible to be treated with siponimod: 1) does not tolerate it due to side effects or safety reasons, or 2) has failed siponimod treatment due to perceived lack of efficacy, or 3) has declined siponimod treatment.

Exclusion criteria

Exclusion Criteria:

  • The participant has a history of infection or may be at risk for infection.
  • The presence of psychiatric disturbance or substance abuse.
  • History, clinical evidence, suspicion or significant risk for thromboembolic events, as well as myocardial infarction, stroke, and/or antiphosholipid syndrome and any participants requiring antithrombotic treatment.
  • Current hypogammaglobulinemia defined by immunoglobulin levels (IgG and/or IgM) below the lower limits of normal (LLN) at Screening or a history of primary hypogammaglobulinemia. Patients with a history of secondary hypogammaglobulinemia induced by anti-C20 monoclonal antibodies (eg, ocrelizumab, ofatumumab, ublituximab, rituximab) may be considered for study inclusion provided their immunoglobulin levels are within the normal limits (WNL) at time of Screening.
  • A history or presence of disease that can mimic MS symptoms, such as, but not limited to neuromyelitis optica spectrum disorder, systemic lupus erythematosus, Sjogren's syndrome, acute disseminated encephalomyelitis, and myasthenia gravis.
  • The participant has sensitivity to any of the study interventions, or components thereof, or has a drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study.
  • The participant was previously exposed to frexalimab.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
943 participants (actual)

Study arms

  • Experimental
    Frexalimab

    Frexalimab IV administration

    Drug: Frexalimab · Drug: MRI contrast-enhancing agents

  • Placebo comparator
    Placebo

    Matching placebo

    Drug: Placebo · Drug: MRI contrast-enhancing agents

Interventions

  • SAR441344 Solution for IV infusion

  • DrugPlacebo

    Solution for IV infusion

  • DrugMRI contrast-enhancing agents

    IV, as per respective label

06

What researchers measure

Primary outcomes

  1. Time to onset of composite confirmed disability progression (cCDP) confirmed over 6 months in the double-blind treatment period

    Defined as Increase from the baseline expanded disability status scale (EDSS) score of ≥1.0 point when the baseline is \<5.5, or ≥0.5 point when the baseline is ≥5.5, OR Increase of ≥20% from the baseline time in the 9 hole peg test (9HPT),OR Increase of ≥20% from the baseline time in the timed 25 foot walk (T25FW) test

    Time frame: Up to 36 months

Secondary outcomes

  1. Time to onset of composite cCDP confirmed over 3 months in the double-blind treatment period

    Time frame: Up to 36 months

  2. Time to onset of individual components of the composite, confirmed over 3-months or 6 months in the double-blind treatment period

    increase from the baseline EDSS score of ≥1.0 point when the baseline is \<5.5, or ≥0.5 point when the baseline is ≥5.5

    Time frame: Up to 36 months

  3. Time to onset of confirmed disability improvement (CDI) in the double-blind treatment period

    defined as decrease from the baseline EDSS score of ≥1.0 or ≥ 0.5 points when baseline is ≤5.5 or \>5.5 points, respectively, confirmed over 6 months.

    Time frame: Up to 36 months

  4. Number of new and/or enlarging T2 hyperintense lesions per year as detected by MRI

    defined as the sum of the individual number of new and/or enlarging T2-hyperintense lesions at all scheduled visits starting after baseline up to the end of double-blind treatment period

    Time frame: Up to 36 months

  5. Percent change in brain volume loss as detected by MRI scans at the end of double-blind treatment period compared to Month 6

    Time frame: Up to 36 months

  6. Change in cognitive function at the end of double-blind treatment period compared to baseline as assessed by symbol digit modalities test (SDMT)

    Time frame: Baseline, Up to 36 months

  7. Change from baseline in multiple sclerosis impact scale 29 version 2 (MSIS-29v2) questionnaire scores over time in the double-blind treatment period

    Time frame: Baseline, Up to 36 months

  8. Change from baseline in patient reported outcome measurement information system (PROMIS) Fatigue multiple sclerosis (MS)-8a over time in the double-blind treatment period

    Time frame: Baseline, Up to 36 months

  9. Annualized relapse rate during the double-blind treatment period assessed by protocol defined adjudicated relapses

    Time frame: Up to 36 months

  10. Number of participants with adverse events, SAEs, AEs leading to permanent study intervention discontinuation and AE of special interests (AESIs)

    Time frame: Up to 36 months

  11. Number of participants with potentially clinically significant abnormalities (PCSAs) in laboratory tests, ECG, and vital signs during the study period

    12-lead ECG (electrocardiogram) will be obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals.

    Time frame: Up to 36 months

  12. Number of participants with antibody over time

    Time frame: Up to 36 months

  13. Change from baseline in serum Ig levels over time

    Time frame: Up to 36 months

  14. Change from baseline in plasma neurofilament light chain (NfL) levels over time in the double-blind treatment period

    Time frame: Up to 36 months

  15. Frexalimab plasma concentration over time in the double-blind treatment period

    Time frame: Up to 36 months

07

Study locations

311 sites

Showing the first 100 of 311 sites across 27 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Mar 2028, 50 months after the start.

Of 71 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's planned 50 months is above that.

Counting every sponsor, half of 96 studies reached it within 42 months; a quarter within 26 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2023
First posted
Nov 21, 2023
StartActual
Dec 27, 2023
Primary completionEst.
Mar 24, 2028
CompletionEst.
Mar 24, 2028
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedNumber of new and/or enlarging T2hyperintenseT2 hyperintense lesions per scanyear as detected by MRI, and number of new and/or enlarging T2-hyperintense lesions per scan as detected by MRITime frame: Up to 36 months
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedNumber of new and/or enlarging T2hyperintenseT2 hyperintense lesions per scanyear as detected by MRI, and number of new and/or enlarging T2-hyperintense lesions per scan as detected by MRITime frame: Up to 36 months
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06141486
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Nov 21, 2023
Start date
Dec 27, 2023
Primary completion
Mar 24, 2028 (estimated)
Completion
Mar 24, 2028 (estimated)
Last update
Nov 9, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Frexalimab

Start the discussion